The COVID-19 testing bubble could be on the verge of popping for Abbott Laboratories. The company is eliminating 310 jobs at its Westbrook, ME manufacturing facility according to a report from Mainebiz.
Cynosure seems to be doing just fine after it was divested from Hologic in 2019. The medical aesthetics company is even getting involved in some acquisitions.The Westford, MA-based company said on Friday it entered into an agreement to acquire the MyEllevate Surgical Suture System, expanding the company’s portfolio of minimally invasive facial rejuvenation solutions.
Marlborough-based CeQur, a maker of insulin delivery devices, has raised $115 million in capital as it gears up to launch its wearable insulin injector later this year.
A new public-private partnership may bring the clinical trial of a dialysis device to the Manchester VA. The device, the CVS Kidney Care’s HemoCare Hemodialysis System developed by DEKA research in Manchester, would allow dialysis patients to complete the process at home.
ABBOTT PARK, Ill., Aug. 26, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott will sell this test for $5. It is highly portable (about the size of a credit card), affordable and provides results in 15 minutes. BinaxNOW uses proven Abbott lateral flow technology, making it a reliable and familiar format for frequent mass testing through their healthcare provider. With no equipment required, the device will be an important tool to manage risk by quickly identifying infectious people so they don’t spread the disease to others.
Source: Abbott’s Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month – Aug 26, 2020
FDA warned earlier this week that Thermo Fisher Scientific’s TaqPath test could have a risk of false results. This follows the Waltham, MA-based company exiting its bid to acquire Qiagen for $12.5 billion.
Many of us have seen and even felt what it’s like to have a test for COVID-19. One Connecticut medical science company saw the national struggle to make tests available, so they took on the challenge.
The Food and Drug Administration on Wednesday opened the door to COVID-19 testing that could be fast, cheap, and handled entirely at home — if companies don’t find the rules too burdensome.
Abbott’s second-quarter earnings showed a mixed bag with pandemic disruptions on the medical device side of the business, and sales of COVID-19 tests driving growth for the diagnostic side.
Candela is driven by an unwavering focus on quality and innovation. For more than 50 years, the company has pioneered breakthroughs using energy-based laser devices for treating a broad range of conditions, from hair removal and wrinkle reduction to traumatic scarring involving wounded warriors and burn victims.
Healthcare worldwide is at an exciting inflection point. On the one hand is reactive medicine, which to a large extent describes the profile of the existing system – you get sick, visit your healthcare provider, get treated and go home.